Clinical study on the treatment of distal ulcerative colitis with Ganyu-Pixu by the therapeutic method of Rougan Jianpi and mesalazine enema
Objective To evaluate the clinical efficacy of Rougan Jianpi therapy combined with Mesalazine enema in the treatment of distal ulcerative colitis(DUC)with Ganyu-Pixu syndrome.Methods This study is a prospective parallel randomized controlled study.From November 2021 to May 2022,115 patients with DUC in Changshu Hospital Affiliated to Nanjing University of Chinese Medicine were selected and randomly divided into a control group of 58 patients and a study group of 57 patients.The control group was treated with Mesalazine enema,and the study group was treated with Rougan Jianpi Decoction on the basis of the control group.Both groups were treated for 8 weeks.The severity of the disease was evaluated by using the Modified Mayo Scale,and the clinical and endoscopic efficacy was evaluated based on the changes in the score before and after treatment.TCM syndromes were scored from four aspects:abdominal pain,diarrhea,mucopurulent bloody stool,Rectal tenesmus,and anal burning.The quality of life was evaluated by using the IBD Quality of Life Scale(IBDQ).The serum TNF-αand IL-10 level were detected by using ELISA method.The adverse reactions during treatment were observed and recorded.Results The total effective rate of the study group was 91.23％(52/57),while that of the control group was 79.31％(46/58).The difference between the two groups was no statistically significant(Z=1.47,P=0.143).The proportion of patients in the study group who achieved clinical response[40.35％(23/57)vs.51.72％(30/58)]and clinical relief[59.65％(34/57)vs.43.11％(25/58)]the total proportion were significantly higher than those in the control group[100.00％(57/57)vs.94.83％(55/58);Z=1.97,P=0.049].The proportion of patients with endoscopic response[52.63％(30/57)vs.56.90％(33/58)]and mucosal healing[33.33％(19/57)vs.17.24％(10/58)]the total proportion in the study group were significantly higher than those in the control group[85.96％(49/57)vs.74.14％(43/58);Z=2.23,P=0.026].after treatment,the IBDQ score[(194.3±15.1)vs.(172.6±18.4),t=6.90]in the study group was significantly higher than that of the control group.After treatment,the patient's TCM symptom score:mucopurulent bloody stool[(1.7±0.8)vs.(2.0±0.6),t=2.03],rectal tenesmus[(1.5±0.6)vs_(1.8±0.6),t=2.32]and anal burning[(1.3±0.6)vs.(1.6±0.7),t=2.38]in the control group were significantly lower than those in the control group(P＜0.05).The level of IL-10[(53.3±8.0)ng/L vs.(49.0±6.7)ng/L,t=3.10]in the study group after treatment was higher than that of the control group(P＜0.01),and TNF-α[(28.3±7.9)ng/L vs.(36.8±8.1)ng/L,t=3.58]was lower than that of the control group(P＜0.01).There were no significant adverse reactions observed during the treatment in both groups.Conclusion Method of Rougan Jianpi combined with mesalazine enema can improve the clinical symptoms of DUC patients,improve clinical efficacy,and have good safety.
Colitis,ulcerativeRougan Jianpi DecoctionEnema therapySyndrome of stagnation of liver qi and spleen deficiency
NETL
NSTL
万方数据
